^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=27, Recruiting, Weill Medical College of Cornell University | Trial completion date: Apr 2028 --> Apr 2030 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Telomelysin (suratadenoturev)
    1d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    1d
    Claudin 18.2 Expression Concordance in Paired Cytology and Surgical Specimens of Gastric and Gastroesophageal Junction Adenocarcinomas. (PubMed, Arch Pathol Lab Med)
    Cytology specimens could serve as a reliable source for CLDN18.2 biomarker testing when interpreted at the threshold of 75% or above. Although discrepancies occur in some cases, the findings support the incorporation of cytology into biomarker testing workflows to expand access to CLDN18.2-targeted therapies for patients lacking surgical specimens.
    Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    2d
    A Comparative Study of the Application of Two Different ICG Fluorescence Biliary Imaging Techniques in Laparoscopic Radical Gastrectomy for Gastric Cancer: A Single-center Non-inferiority Randomized Controlled Study (ChiCTR2600121753)
    P=N/A, N=658, Recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial • Head-to-Head
    2d
    A Single-Arm, Exploratory Clinical Study on the Impact of β-Blockers on the Efficacy of Immunotherapy for Gastric Cancer (ChiCTR2600121569)
    P=N/A, N=33, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    2d
    The effects of oral nutritional supplements containing high levels of DHA on the nutritional status and physical function of gastric adenocarcinoma patients undergoing chemotherapy (ChiCTR2600121323)
    P=N/A, N=194, Shandong Provincial Hospital; Shandong Provincial Hospital
    New trial
    2d
    To evaluate the safety and efficacy of Apololitowereili Monoclonal Antibody combined with FLOT regimen in patients with locally advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma. (ChiCTR2600120362)
    P2, N=29, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • HER-2 negative
    |
    apalutamide
    2d
    A Two-Way Nested Case-Control Study on the Diagnosis of Sensitivity to Neoadjuvant Chemotherapy Combined with Immunotherapy in Advanced Gastric Cancer Based on Proteomics/Phosphoproteomics (ChiCTR2600120271)
    P=N/A, N=270, Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine; Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine
    New trial
    2d
    Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy with VRT106 versus PIPAC in Patients with Advanced Gastric Cancer and Peritoneal Metastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial (ChiCTR2600120242)
    P=N/A, N=30, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New trial
    2d
    Long-term outcomes of endoscopic full-thickness resection plus laparoscopic regional lymph node dissection versus conventional gastrectomy for cT1bN0 early gastric cancer: a prospective real-world study (ChiCTR2600120034)
    P=N/A, N=30, Peking University Cancer Hospital; Peking University Cancer Hospital
    New trial • Real-world evidence
    2d
    A single-arm, single-center, phase II clinical study on microwave ablation combined with immune checkpoint inhibitors in the treatment of oligometastatic advanced gastric/gastroesophageal junction adenocarcinoma (ChiCTR2600119537)
    P2, N=22, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial • Checkpoint inhibition
    2d
    A Study on the Efficacy and Safety of Sintilimab Combined with Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients with Short-term Recurrence after Adjuvant Therapy (ChiCTR2600119362)
    P2, N=30, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Tyvyt (sintilimab) • Cyramza (ramucirumab)